Jesper Soderqvist - Boule Diagnostics CEO Pres

BOUL Stock  SEK 7.38  0.62  9.17%   

Insider

Jesper Soderqvist is CEO Pres of Boule Diagnostics AB
Age 57
Phone46 87 44 77 00
Webhttps://www.boule.com

Boule Diagnostics Management Efficiency

The company has return on total asset (ROA) of 0.0271 % which means that it generated a profit of $0.0271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0335 %, meaning that it generated $0.0335 on every $100 dollars invested by stockholders. Boule Diagnostics' management efficiency ratios could be used to measure how well Boule Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.
Boule Diagnostics AB has accumulated 50.6 M in total debt with debt to equity ratio (D/E) of 46.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Boule Diagnostics has a current ratio of 1.27, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Boule Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Boule Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Boule Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Boule to invest in growth at high rates of return. When we think about Boule Diagnostics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jens VellingBioGaia AB
N/A
Julien VeyssyCellaVision AB
40
Lars LevinC Rad AB
52
Ola HaggfeldtCTT Systems AB
54
Linda HagglundBioGaia AB
50
Xiaodong WangC Rad AB
44
Markus BergCTT Systems AB
43
Simon OstergaardCellaVision AB
52
Maja NilssonBiotage AB
N/A
Tony RosendalCTT Systems AB
56
Raffaella BombardaBiotage AB
49
Scott CarrBiotage AB
56
Henrik HojerCTT Systems AB
56
Peter LandquistCTT Systems AB
65
Eva NelsonBioGaia AB
N/A
Urban StrindlovCellaVision AB
59
Jonas StahlbergBiotage AB
48
Yve ThorenburgCellaVision AB
65
JonSverre SchancheBiotage AB
66
Ivan AstralagaC Rad AB
N/A
CS BScBiotage AB
50
Boule Diagnostics AB , a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. Boule Diagnostics AB was founded in 1956 and is headquartered in Spnga, Sweden. Boule Diagnostics operates under Image Processing classification in Sweden and is traded on Stockholm Stock Exchange. Boule Diagnostics AB (BOUL) is traded on Stockholm Exchange in Sweden and employs 200 people.

Management Performance

Boule Diagnostics Leadership Team

Elected by the shareholders, the Boule Diagnostics' board of directors comprises two types of representatives: Boule Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boule. The board's role is to monitor Boule Diagnostics' management team and ensure that shareholders' interests are well served. Boule Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boule Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Annette Colin, VP CFO
Helena Borjesson, Chief Officer
Kiarash Farr, Director of Commercial Operations
Karen Bornstein, North Marketing
Aishat Bislieva, VP Culture
Jesper Soderqvist, CEO Pres
Mikael Ekholm, VP Production
Michael Eliott, Head Consumables
Mattias Isaksson, VP Marketing
Christina Hugosson, Head Systems

Boule Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boule Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Boule Stock Analysis

When running Boule Diagnostics' price analysis, check to measure Boule Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boule Diagnostics is operating at the current time. Most of Boule Diagnostics' value examination focuses on studying past and present price action to predict the probability of Boule Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boule Diagnostics' price. Additionally, you may evaluate how the addition of Boule Diagnostics to your portfolios can decrease your overall portfolio volatility.